Acute and Subacute Ischemia of Lower Limbs: Angiographyand Peripheral Hemodynamics. Bulvas M, Sommerová Z.

Acute and Subacute Ischemia of Lower Limbs:

6 Angiography and Peripheral Hemodynamics

- 8 Running title: Acute and subacute limb ischemia
- 9 Miroslav Bulvas, MD. PhD. Assoc. Prof.
- 10 Zuzana Sommerová, MD. PhD.
- 12 Affiliations:

3 4

5

7

11

16

20 21

23

27

29

33 34

35 36 37

38

- 13 Miroslav Bulvas, Department of Surgery, Division of Angiology, University Hospital
- 14 Královské Vinohrady, Third Faculty of Medicine, Charles University (address: Šrobárova 50,
- 15 100 34, Prague 10, Czech Republic)
- 17 Zuzana Sommerová, Center for Cardiovascular Prevention, First Faculty of Medicine and
- 18 Thomayer Hospital, Charles University (address: Vídeňská 800, 140 59 Prague 4, Czech
- 19 Republic), email: zuzanasommerova@mybox.cz
- 22 Corresponding author: Miroslav Bulvas, email: bulvasm@seznam.cz
- 24 miroslav.bulvas@lf3.cuni.cz
- 25 phone: +420 603426473
- address: U Michelského mlýna 35, 140 00 Prague 4,
 - Czech Republic
- 28 ORCID iD: 0000-0003-4211-6696

30 Acknowledgments

The authors thank Candance McClure (NAMSA, Toledo, OH, USA) and Marian Rybář (MATSTAT, Prague, Czech Republic) for statistical expertise.

<u>Declaration of Conflicting Interests:</u> The authors have no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors recieved no financial support for the research, authorship, and/or publication of this article.

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

2

ABSTRACT Objective: To identify pretreatment characteristics related to ischemia severity and symptoms duration in patients with acute (ALI) and subacute lower limb ischemia (SLI). Methods: Comparative study, a part of prospective, single-arm, single-center trial of 316 consecutive patients with threatened extremities (all-comers, mean age: 70.9±12.0 years, range: 23-96; 184 men) of whom 99. 4 % suffered from acute or subacute supratibial occlusions (target occlusions). Results: Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The value of ABI related to the number of occluded tibial arteries. Occlusion locations associated with ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Furthermore, ALI subjects presented additional infrapopliteal occlusion (acute and/or subacute), smaller number of patent tibial arteries and lower ABI. **Conclusion:** Anatomically, the most important factor related to the ischemia severity and symptoms duration was the status of infrapopliteal vascular bed. The number of acutely, subacutely or chronically occluded tibial vessels was related to clinical categories of ALI and SLI and to ABI. This suggests that tibial reperfusion can be essential for the salvage of threatened limb and should be always considered.

INTRODUCTION

Acute lower limb ischemia (ALI) is a critical vascular emergency that endangers the affected extremity and puts the patient's life at risk. It is defined as a sudden decrease in or worsening of limb perfusion that has been present for 14 days or less and causing a potential threat to limb viability^{1,2}.

The clinical presentation of ALI is not single and varies from viable to irreversibly damaged extremity. The limb can be threatened immediately after the symptoms origin or later when ischemia progresses, steadily or in steps. The fact that suddenly developed ischemia can escalate during the time period longer than 2 weeks, led many authors to use the term "subacute limb ischemia" (SLI) to distinguish the unstable and developing condition from the chronic, stable ischemic status. The guidelines^{3,4} defined SLI by symptoms duration longer than 14 days, and lasting up to 3 months.

The pre-treatment factors, reported in the literature^{5,6} to influence the mortality and amputation rates were high age, female gender, non-Caucasian race, comorbidities (diabetes, malignancy, neurological disorders, coronary heart disease, congestive heart disease), multilevel occlusion, more proximal occlusions, limb ischaemia severity, treatment risk and urgency, tissue damage, repeated ALI attacks, absence of early anticoagulation and delay in diagnosis and revascularization. However, their role and incidence may differ in patients with different clinical presentation.

Because the same initial treatment techniques (open surgery, catheter-directed thrombolysis, mechanical thrombectomy) are used in patients with ALI or SLI ⁷, different number of patients with SLI and those with ALI categorized as type I (viable extremity), IIA (marginally threatened) or IIB (immediately threatened) have been often grouped in ALI cohorts in studies to date analyzing surgical and/or endovascular treatment outcomes. To understand whether such a grouping can affect the overall results and comparability among the studies, it is important to learn more about characteristic of individual clinical categories.

Closer knowledge is necessary for better understanding the high mortality and amputation rates, and the factors associated with or responsible for clinical presentation, serious events and technical failure of therapeutic intervention.

The aim of this study was to identify the relations of ischemia severity and/or symptoms duration with age, gender, comorbidities, clinical presentation, arterial occlusion aetiology, vascular anatomy and peripheral hemodynamics in patients with threatened lower extremity due to ALI (IIA, IIB) or SLI. Specifically, we focused on the role of infrapopliteal arterial patency in 316 patients (all-comers) of whom 99. 4 % primarily suffered from acute or subacute supratibial occlusions (target occlusions).

MATERIAL AND METHODS

Our study was a single-centre, prospective, single-arm trial performed during the time interval 2009–2015 with two main goals. The first part documented the efficacy, safety and applicability of endovascular removal of occlusive material as the initial treatment in patients with limb threatening ALI and SLI. It was already published ⁸.

In this report, we focused on pre-treatment difference between clinical categories (ALI vs. SLI, ALI IIB vs. ALI IIA, females vs. males, thrombotic occlusion vs. embolism). We compared demographic data, frequencies of risk factors and comorbidities, clinical data, ankle-brachial pressure index (ABI) and vascular anatomy characteristics (Table 1, 2).

The target lesion and vascular anatomy information was obtained by digital subtraction angiography in all patients. No therapeutic interventions were performed or tested in this part of the study.

The study included 316 consecutive patients (all-comers, 184 men, mean age: 70.9 ± 12.0 years): 202 subjects with ALI (114 men, mean age: 72.6 ± 12.2 , mean symptoms duration: 4.13 ± 4.47 days; 146 patients categorized as IIB of the Rutherford classification for acute limb ischaemia²; 56 patients of the category IIA) and 114 patients with SLI (70 men,

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

5

(SD). Categorical data are given as the number (percentage). Continuous variables were

compared using a paired or unpaired t test or Wilcoxon rank sum test, as appropriate. Categorical variables were analyzed using a 2 -sided chi-square or Fischer exact test, as appropriate. For analysis of variance (ANOVA), Welch's test for unequal sample sizes was used. The threshold of statistical significance was p <0.05. Statistical analyses were performed using SAS software (version 9.4; SAS Institute, USA) and STATSOFT software for Welch's test (Statistica, version 10, USA).

RESULTS

Anatomy

The presence of acute or subacute supratibial arterial occlusions was documented in 314 (99.4 %) of 316 patients with threatened lower limbs due to ALI and SLI. Mean length of supratibial occlusion was greater in group with ALI (244.6 mm) vs. SLI (202.0 mm), p=0.0159 and in patients with thrombotic cause of the occlusion (246.6 mm) vs. embolism (155.0 mm, p<.0001).

The most frequently occluded (acutely or subacutely) locations were the femoropopliteal segment (in 73.1 % of 316 patients) and femoropopliteal bypass (22.8%). Significant difference in frequency of femoropopliteal segment and femoropoplital bypass occlusion was not documented between patients with ALI vs. SLI and ALI IIB vs. ALI IIA (Table 1).

The aortoiliac segment occlusion was detected in 11.1 % of all patients, with higher incidence in those with ALI (13.9 %) vs. SLI (6.1 %, p=.0401) (Table 2). The incidence of the deep femoral artery occlusion was higher in patients with ALI vs. SLI (12.9 vs. 5.3 %, p=0.0332), embolism vs. thrombosis (23.3 vs. 7.0 %, p=.0006) and females vs. males (15.2 vs. 6.5%, p=.0142) (Table 2).

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

in the subgroups with ABI value from 0.2-0.5 (Fig 2).

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

8

p=.0151), in-stent occlusion (27.7 vs. 5 %, p<.0001), femoropopliteal bypass occlusion (27.1

vs. 1.7 %, p<.0001) higher number of patent calf vessels (1.0 vs. 0.4, p<.0001) and higher ABI (0.14 vs. 0.07, p=.0016) (Table 5,6).

Risk factors and concomitant disease

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Comparison between patients with SLI and ALI detected significantly higher frequency of the smoking history (64.0 vs. 49.0 %, p=.0134), claudication (53.5 vs. 15.3 %, p<.0001) and tissue defect (22.8 vs.10.4 %, p=.0047). The ALI patients were older (mean age: 72.6 vs. 67.9 years, p=.0005), with longer target lesion (mean length: 244.6 vs. 202.0 mm, p=.0159), higher frequency of rest pain (83.7 vs. 57.9 %, p<.0001), embolism (24.8 vs. 8.8 %, p=.0005), arrhythmias (30.7 vs. 16.7 %, p=.0071). A higher statistical trend toward increased incidence of cardiac disease (46.0 vs. 35.1 %, p=.0749), cerebrovascular disease (28.2 vs.19.3 %, p=.0809) and renal insufficiency (26.7 vs. 17.5 %, p=.0726) was detected in ALI subjects (Table 1,2). Comparison between ALI patients with immediately (IIB) and marginally (IIA) threatened extremities detected significantly higher frequency of diabetes (36.3 vs. 21.4 %, p=.0452), rest pain (91.8 vs. 62.5 %, p<.0001), embolism (28.8 vs. 14.3 %, p=.0442) in II B subjects, together with lower mean number of patent calf vessels (0.4±0.9 vs. 1.4±1.1, p<.0001), ankle-brachial index $(0.0\pm0.1 \text{ vs. } 0.2\pm0.2, \text{ p}<.0001)$ and shorter mean duration of the ischaemic symptoms (3.1 vs. 6.8 days, p=.0004). Patients with ALI IIB also presented higher incidence of the cerebrovascular disease (32.2 vs. 17.9 %, p=.0543) and the renal insufficiency (26.7 vs. 17.5 %, p=.0726), but those differences were beyond the statistical significance (Table 3,4). Subjects with ALI IIA presented higher frequency of smoking history (60.7 vs. 44.5 %, p=.0425), hyperlipidaemia (50.0 vs. 32.9 %, p=.0344), claudication (39.3 vs. 6.2 %,

Gender: Females vs. males

Female gender was associated with higher mean age (75.1 vs. 67.9 years, p<.0001), higher incidence of hypertension (81.1 vs. 70.1 %, p=.0355), arrhythmias (34.8 vs. 19.0 %, p=.0017) and embolism (29.5 vs. 11.4 %, p<.0001) as the cause of target arterial occlusion. Additionally, the occlusion was more frequently located in the femoropopliteal arterial segment (79.5 vs. 68.5 %, p=.0296) and the deep femoral artery (15.2 vs. 6.5 %, p=.0142) in this subgroup. Male subgroup presented more frequent smoking history (67.4 vs. 36.4 %, p<.0001), renal insufficiency (27.7 vs. 17.4 %, p=.0429), tissue defect (18.5 vs. 9.8 %, p=.0375), thrombotic cause of the occlusion (88.6 vs. 70.5 %, p<.0001) and femoropopliteal bypass occlusion (28.8 vs. 14.4 %, p=.0027). A higher statistical trend in favour of claudication (33.2 vs. 23.5 %, p=.0785) was also detected in this subgroup (Table 7).

Clinical presentation

Comparison between ALI patients with immediately (IIB) and marginally (IIA) threatened extremities detected significantly shorter mean duration of the ischaemic symptoms (3.1 vs. 6.8 days, p=.0004). The incidence of tissue defects was higher in males (18.5 % vs. 9.8 %, p=.0375), SLI vs. ALI (22.8 .vs 10.4 %, p=.0047), patients with thrombosis vs. embolism (17. 2 vs. 5.0 %, p=.0151). The rest pain occurred more frequently in ALI group (83.7 % vs. 57.9 %, p<.0001), and in ALI IIB vs. ALI IIA (91.8 vs. 62.5 %, p<.0001). The claudication was detected in 53.5 % of subjects with SLI (vs. 15.3 % in ALI, p<.0001), 39.3 % of ALI IIA (vs. 6.2 % in ALI IIB, p<.0001) and in patients with thrombosis (32.4 %) vs. embolism (15.0 %, p=.0071) (Table 1,3,5,7).

DISCUSSION

Ischaemia severity, symptoms duration and their progression in time vary with the grade and dynamics of blood flow deterioration. Vessel anatomy before ALI attack, site and cause of acute arterial occlusion, collateral development, embolus fragmentation and its displacement to the peripheral branches, thrombosis progression, runoff quality and antithrombotic therapy are the factors influencing clinical presentation of ALI. Together with serious comorbidities, they affect periprocedural, early and long-term treatment outcomes, morbidity, mortality and amputation rates. Detailed angiography description and pretreatment ABI data were often not presented in the study reports dedicated to surgical and/or endovascular therapy of ALI. Thus, the correlation of ischaemic symptoms and their duration with the limb hemodynamics and vascular anatomy is difficult or impossible from the literature.

In retrospective analysis of 160 ALI patients (symptoms duration 7 days or less, 13 % embolic and 87 % thrombotic occlusions, 75 % clinical category II) managed with 186 intraarterial thrombolytic procedures, McNamara and colleagues¹² correlated angiographic patterns with clinical severity of ischemia. They based the angiographic categorization on the number of occluded arterial segments (common iliac, external iliac, common femoral, superficial femoral, popliteal, trifurcation, bypass grafts), presence of visible patent distal vessels, existence of patent collateral vessels, and the occurrence of stenoses involving inflow, collateral, or outflow vessels. Clinical category "viable" (I) correlated with single-segment occlusion, patent collaterals and distal vessels. Patients requiring blood to flow through two contiguous collateral beds to supply distal vessels or with single occlusion combined with stenosis of the adjacent inflow, outflow or collateral vessel correlated with the clinical category "threatened" (II). Occlusions of more than two segments with distal propagation that occluded the distal vascular bed correlated with the clinical category "irreversible" (III).

30 days.

In their study of 45 patients with embolic occlusions managed by thrombolysis, Huettl and Soulen¹³ detected no patent calf vessels in 56 % of patients, one calf vessel was patent in 22 %, two in 7 % and three in 16 % of patients before treatment. Those numbers are close to our data. Using thrombolysis and additional endovascular techniques for treatment of nonembolic ALI in 119 patients (72 % grafts, 68 % category I), Kashyap and associates¹⁴ detected multisegmental thrombosis in 16 % and tibial thrombosis in 22 % of patients. Distal occlusions beyond the reach of the rheolytic catheter limited the treatment in 57 % of 86 patients with ALI or SLI in the study of Kasirajan et al¹⁵. The need for distal thrombectomy and poor intra-operative runoff were detected among risk factors for amputation and death in 107 patients with ALI undergoing infrainguinal bypass¹⁶. Also, any patent pedal outflow was a significant predictor for technical success in patients with ALI managed surgically (296 pts) or by endovascular technique (147 pts) in the study of Taha and associates¹⁷. Failed mechanical recanalization of the diffusely occluded infrapopliteal vascular bed influenced the need for thrombolytic therapy, the rate of major bleeding, treatment outcomes, amputation and mortality rates in patients with ALI and SLI⁸.

The greatest mean lesion lengths were reported in the studies of ALI and SLI patients with target occlusions located in the femoropopliteal bypass (32.1; 28.4 cm)^{18,19}. In our series, the mean length of the target occlusion was 22.9 cm and 22. 8 % of 316 patients suffered from occluded femoropopliteal bypass.

The comparison between patients with embolic vs. thrombotic cause of arterial occlusions, we documented higher age, higher frequency of female gender, cardiac disease, arrhythmias, ALI, ALI IIB, occlusions of femoropopliteal segment and/or profunda femoris in subjects with embolism. They also presented higher frequency of additional infrapopliteal

historical view that embolism produces more severe ischaemia than thrombosis was

confirmed.

Thrombosis subgroup presented higher incidence of male gender, smoking history, subacute ischemia, acute ischemia IIA, claudication, tissue defect, femoropopliteal bypass and in-stent occlusions. Furthermore, these patients presented greater mean occlusion length, higher ABI and number of patent calf vessels. Aune and Trippestad²⁰ reported in their study of 272 patients managed by embolectomy (192 pts. with embolism) or bypass (80 pts. with thrombosis), a higher mean age, frequency of female gender and cardiac disease, together with shorter life expectancy in patients with embolism. Kuukasjarvi et al. in their study of 509 ALI patients (without previous reconstructions) from National Vascular Registry²¹ detected higher frequency of embolism in patients of age 75 or more years and smoking as a risk factor for acute thrombosis. The authors speculated that the worse prognosis (higher amputation rate, mortality rates and necessity for repeated interventions) of patients with acute thrombotic occlusion was associated with advanced atherosclerosis.

Higher age and frequency of hypertension, arrhythmias, embolism, occlusions of femoropopliteal segment and deep femoral artery were associated with female gender. Smoking history, renal insufficiency, tissue defects, thrombosis as a cause of the occlusion and femoropopliteal bypass occlusion were more frequent in patients of male gender. Additionally, we observed statistical trend toward more frequent claudication in the male group.

Similar results can be found in the literature. Braithwaite and colleagues²² managed 84 elderly patients (75-100 years) with ALI by surgery and/or thrombolysis. Percentage of females was 71.4 % in their series and female preponderance was greatest (84.8 %) in the subgroup selected for immediate embolectomy. Female predominance was detected also in

CONCLUSION:

Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The value of ABI related to the number of occluded tibial arteries.

The most frequent locations of supratibial occlusions were femoropopliteal segment (73.1 %) and femoropopliteal bypass (22.8 %) without significant difference in clinical categories. Occlusion locations related to ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Also, more ALI subjects presented additional infrapopliteal occlusion (acute and/or subacute) and lower number of patent tibial arteries and lower ABI.

Anatomically, the important factor related to the ischaemia severity and symptoms duration was the status of infrapopliteal vascular bed. The number of patent or acutely, subacutely and chronically occluded tibial vessels related to individual clinical categories of ALI and SLI and to ABI. This suggests that tibial repefusion can be essential for the salvage of threatened limb and should be always considered.

Patients with the most severe ischaemia and immediately threatened extremity (ALI IIB) presented shortest symptoms duration, higher frequency of rest pain, embolism, diabetes, additional acute infrapopliteal occlusion, lower number of patent tibial vessels and lower ABI in comparison with ALI IIA patients. More frequent diabetes can participate on higher number of occluded tibial vessels in this subgroup.

On the other hand, more patients with thrombosis, smoking history, hyperlipidemia, claudication, higher number of patent calf vessels and higher ABI were detected in ALI IIA subgroup.

In comparison with ALI group, the subjects with SLI presented more frequently the thrombosis as a cause of target occlusion, smoking history, claudication, tissue defects, shorter target occlusion, lower number of occluded tibial vessels and higher ABI. Furthermore, they presented younger age, less embolism and arrhythmias, less aortoiliac segment and deep femoral artery occlusions.

Embolism as a cause of the supratibial arterial occlusion was associated with higher age, female gender, cardiac disease, arrhythmias, ALI, ALI IIB, femoropopliteal segment and deep femoral artery occlusions, infrapopliteal occlusions, lower ABI and number of patent calf vessels. Higher ischaemia severity in subjects with embolism was not associated only with the fact that embolus suddenly occluded healthy supratibial artery but also with higher frequency of additional infrapopliteal occlusion, profunda femoris occlusion and the higher number of occluded tibial vessels. The data confirmed a historical view that the most severe ischemia occurs with the embolism.

Thrombosis was associated with smoking history, SLI, ALI IIA, claudication, tissue defects, longer target lesion, femoropopliteal bypass occlusion, in-stent occlusion, higher ABI and number of patent calf vessels.

395 arrhythmias, embolism, femoropopliteal and profunda femoris occlusions. Male group

396 manifested a higher frequency of smoking history, renal insufficiency, tissue defect,

- thrombosis and femoropopliteal bypass occlusion.
- 398 Grouping the patients categorized in different clinical categories of ALI and SLI can
- 399 affect the treatment outcomes.

REFERENCES

397

400

401

- 402 1. Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of
- 403 peripheral arterial diseas (TASC II). Eur J Vasc Endovasc Surg 2007;33, suppl 1:S1-S75.
- 2. Rutherford RB, Baker JD, Ernst C et al. Recommended standards for reports dealing with
- lower extremity ischemia: Revised version. J Vasc Surg 1997;26:517-538.
- 406 3. Patel N, Sacks D, Patel RI et al. SCVIR reporting standards for the treatment of acute limb
- 407 ischemia with use of transluminal removal of arterial thrombus. J Vasc Interv Radiol
- 408 2001;12:559-570.
- 4. Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improvement guidelines for
- 410 percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for
- 411 acute lower-limb ischemia. Cardiovasc Intervent Radiol 2011;34:1123-1136.
- 5. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. Surgery
- 413 1998;124:336-342.
- 6. Henke PK. Contemporary management of acute limb ischemia: factors associated with
- amputation and in-hospital mortality. Semin Vasc Surg 2009;22:34-40.
- 416 7. Dosluoglu HH, Harris LM. Endovascular management of subacute lower extremity
- 417 ischemia. Semin Vasc Surg 2008;21:167-179.
- 8. Bulvas M, Sommerová Z, Vaněk I, Weiss J. Prospective single-arm trial of endovascular
- 419 mechanical debulking as initial therapy in patients with acute and subacute lower limb
- ischemia: one-year outcomes. J Endovasc Ther 2019;26:291-301.
- 421 9. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management
- 422 of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal
- 423 aortic): executive summary. A collaborative report from the American Association for
- 424 Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and
- 425 Interventions, Society for Vascular Medicine and Biology, Society of Interventional
- Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to
- 427 Develop Guidelines for the Management of Patients With Peripheral Arterial Disease).
- 428 Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation;
- National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-
- 430 Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:1239–
- 431 1312.

- 434 treatment of peripheral artery diseases: document covering atherosclerotic disease of
- extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The
- 436 Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European
- 437 Society of Cardiology (ESC). Eur Heart J 2011;32:2851–2906.
- 11. O'Connell JB, Quiňones-Baldrich WJ. Proper evaluation and management of acute
- embolic versus thrombotic limb ischemia. Semin Vasc Surg 2009;22:10-16.
- 441 12. McNamara TO, Gardner KR, Bomberger RA, Greaser LE. Clinical and angiographic
- selection factors for thrombolysis as initial therapy for acute lower limb ischemia. J Vasc
- 443 Interv Radiol 1995;6(suppl):36S-47S.
- 13. Huettl EA, Soulen MC. Thrombolysis of lower extremity embolic occlusions: a study of
- the results of the Star Registry. Radiology 1995;197:141-145.
- 448 14. Kashyap VS, Gilani R, Bena JF, Bannazadeh M, Sarac TP. Endovascular therapy for
- acute limb ischemia. J Vasc Surg 2011;53:340-46.
- 451 15. Kasirajan K, Gray B, Beavers FP, Clair DG, Greenberg R, Mascha E, Ouriel K. Rheolytic
- 452 thrombectomy in the management of acute and subacute limb-threatening ischemia.
- 453 J Vasc Interv Radiol 2001; 12:413–421.
- 455 16. Marqués de Marino P, Martínez López I, Revuelta Suero S et al. Results of infrainguinal
- bypass in acute limb ischaemia. Eur J Vasc Endovasc Surg 2016;51:824-30.
- 458 17. Taha AG, Byrne RM, Avgerinos ED, Marone LK et al. Comparative effectiveness of
- 459 endovascular versus surgical revascularization for acute lower extremity ischemia J Vasc Surg
- 460 2015;61:147-54.

438

444

447

450

454

457

461

469

472


476

- 462 18. Hundt W, Kalinowski M, Stamm AC, Portig I, Swaid Z, Dietz C, Geks J, Burbelko M.
- 463 Combined treatment of subacute and acute synthetic and venous bypass-graft occlusions with
- percutaneous mechanical thrombectomy and thrombolysis. Eur J Radiol 2013;82:e807–e815.
- 465 doi: 10.1016/j.ejrad.2013.08.016
- 466 19. Wissgott C, Kamusella P, Andresen R. Recanalization of acute and subacute venous and
- 467 synthetic bypass-graft occlusions with a mechanical rotational catheter. Cardiovasc Intervent
- 468 Radiol 2013;36:936–942.
- 470 20. Aune S, Trippestad A. Operative mortality and long-term survival of patients operated on
- for acute lower limb ischaemia. Eur J Vasc Endovasc Surg 1998;15:143-146.
- 21. Kuukasjarvi P, Salenius J.P and the Finnvasc study group. Perioperative outcome of acute
- lower limb ischaemia on the basis of the National Vascular Registry. Eur J Vasc Surg
- 475 1994;8:578-583.
- 477 22. Braithwaite BD, Davies B, Birch PA, Heather BP, Earnshaw JJ. Management of acute leg
- ischaemia in the elderly. Brit J Surg 1998;85:217-220.

- institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann
- 482 Surg 2003;238:382-390.

485


- 483 24. Kuoppala M, Franzén S, Lindblad B, Acosta S. Long-term prognostic factors after
- thrombolysis for lower limb ischemia. J Vasc Surg 2008;47:1243-1250.
- 486 25. Earnshaw JJ, Whitman B, Foy C for the Thrombolysis Study Group. National Audit of
- Thrombolysis for Acute Leg Ischemia (NATALI): Clinical factors associated with early
- 488 outcome. J Vasc Surg 2004;39:1018-25.



Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Number of patent calf vessels before treatment	n Mean ± SD	316 0.9 ± 1.1	114 1.3 ± 1.2	$202 \\ 0.7 \pm 1.0$	<.0001
Patients with no patent tibial vessels	% (n/N)	51.9% (164/316)	33.3% (38/114)	62.4% (126/202)	0.0001
Patients with 1 patent tibial vessel	% (n/N)	17.7% (56/316)	22.8% (26/114)	14.9% (30/202)	0.0914
Patients with 2 patent tibial vessels	% (n/N)	16.5% (52/316)	21.9% (25/114)	13.4% (27/202)	0.0581
Patients with 3 patent tibial vessels	% (n/N)	13.9% (44/316)	21.9% (25/114)	9.4% (19/202)	0.0036


Fig. 1. ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)

ABI in Subacute and Acute Ischemia




Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
ABI before	n	309	108	201	<.0001
treatment	$Mean \pm SD$	0.1 ± 0.2	0.2 ± 0.2	0.1 ± 0.1	
ABI 0-0.1	% (n/N)	57% (176/309)	31.4% (34/108)	71.2% (143/201)	<.0001
ABI 0.11-0.2	% (n/N)	8.7% (27/309)	7.6% (8/108)	9.0% (18/201)	0.8302
ABI 0.21-0.3	% (n/N)	14.2% (44/309)	25.7% (28/108)	8.5% (17/201)	0.0001
ABI 0.31-0.4	% (n/N)	13.9% (43/309)	23.8% (26/108)	8.0% (16/201)	0.0002
ABI 0.41-0.5	% (n/N)	4.5% (14/309)	8.6% (9/108)	2.5% (5/201)	0.0236
ABI 0.51-0.6	% (n/N)	1.3% (4/309)	2.8% (3/108)	0.5% (1/201)	0.1245
ABI 0.61-0.7	% (n/N)	0.3% (1/309)	0% (0/108)	0.5% (1/201)	

Fig. 2. Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 - 0.5), SLI is more frequent.



Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI)								
Welch ANOVA test (p<0.001)								
SLI tibial vessels patent	ABI	ABI SLI	ABI SLI	ABI SLI	ABI SLI			
	SLI	N	SD	Minimum	Maximum			
	Means							
0	0.139	37	0.160	0	0.420			
1	0.214	21	0.129	0	0.450			
2	0.244	25	0.156	0	0.460			
3	0.346	24	0.150	0	0.600			
All Groups	0.229	107	0.168	0	0.600			

Fig. 3. The number of patent tibial vessels significantly (p<.001) correlates to ABI in SLI patients.



Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI)								
Welch ANOVA test (p<0.001)								
ALI tibial vessels patent	ABI	ABI	ABI ALI	ABI ALI	ABI ALI			
	ALI	ALI	SD	Minimum	Maximum			
	Means	N						
0	0.032	125	0.090	0	0.460			
1	0.150	30	0.165	0	0.460			
2	0.151	27	0.173	0	0.560			
3	0.149	19	0.176	0	0.620			
All Groups	0.081	201	0.140	0	0.620			

Fig. 4. Also in ALI patients, the number of patent tibial vessels significantly (p<.001) correlates to ABI.

LEGENDS

- Fig. 1. ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD standard deviation, vss-vessel(s)
- Fig. 2. Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 0.5), SLI is more frequent.
- Fig. 3. The number of patent tibial vessels significantly (p<.001) correlates to ABI in SLI patients.
- Fig. 4. Also in ALI patients, the number of patent tibial vessels significantly (p<.001) correlates to ABI.
- Table 1. Demography, concomitant disease, ischemia classification and symptoms: SLI vs. ALI
- Table 2. Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI
- Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB
- Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB
- Table 5. Demographics, concomitant disease, ischemia classification and symptoms: thrombosis vs. embolism
- Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism
- Table 7. Age, concomitant disease, symptoms, ischemia classification, occlusion length and location: female vs. male gender

Table 1. Demography, concomitant disease, ischaemia classification and symptoms: SLI vs. ALI

Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Age (years)	n Mean ± SD Median Range	$31670.9 \pm 12.071.023.0, 96.0$	114 67.9 ± 10.9 67.0 31.0, 94.0	$202 \\ 72.6 \pm 12.2 \\ 73.0 \\ 23.0, 96.0$	0.0005
Male	% (n/N)	58.2% (184/316)	61.4% (70/114)	56.4% (114/202)	0.4079
Diabetes	% (n/N)	30.7% (97/316)	28.1% (32/114)	32.2% (65/202)	0.5256
Smoking history	% (n/N)	54.4% (172/316)	64.0% (73/114)	49.0% (99/202)	0.0134
Hyperlipidaemia	% (n/N)	38.9% (123/316)	41.2% (47/114)	37.6% (76/202)	0.5496
Hypertension	% (n/N)	74.7% (236/316)	73.7% (84/114)	75.2% (152/202)	0.7884
Cardiac disease	% (n/N)	42.1% (133/316)	35.1% (40/114)	46.0% (93/202)	0.0749
Arrhythmias	% (n/N)	25.6% (81/316)	16.7% (19/114)	30.7% (62/202)	0.0071
Cerebrovascular disease	% (n/N)	25.0% (79/316)	19.3% (22/114)	28.2% (57/202)	0.0809
Malignant disease	% (n/N)	7.3% (23/316)	7.9% (9/114)	6.9% (14/202)	0.8226
Renal insufficiency	% (n/N)	23.4 % (74/316)	17.5 % (20/114)	26.7 % (54/202)	0.0726
Acute limb ischaemia category IIA	% (n/N)	17.7% (56/316)		27.7% (56/202)	
Acute limb ischaemia category IIB	% (n/N)	46.2% (146/316)		72.3% (146/202)	
Subacute limb ischaemia	% (n/N)	36.1% (114/316)	100% (114/114)		
Symptoms duration	days	70.9±12.0	44.3±27.3	4.13±4.47	<.0001
Claudication	% (n/N)	29.1% (92/316)	53.5% (61/114)	15.3% (31/202)	<.0001
Rest pain	% (n/N)	74.4% (235/316)	57.9% (66/114)	83.7% (169/202)	<.0001
Tissue defect	% (n/N)	14.9% (47/316)	22.8% (26/114)	10.4% (21/202)	0.0047

Table 2 Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI

Characteristics	Summary Statistics	All Subjects	Sub-Acute Ischemia	Acute Ischemia	p-value
Target occlusion length (mm)	n Mean ± SD Median Range	316 229.2 ± 148.1 200.0 $15.0, 650.0$	114 202.0 ± 136.7 150.0 15.0, 650.0	202 244.6 ± 152.4 200.0 20.0, 590.0	0.0159
Target occlusion cause: Embolism	% (n/N)	19.0% (60/316)	8.8% (10/114)	24.8% (50/202)	0.0005
Target occlusion cause: Thrombosis	% (n/N)	81.0% (256/316)	91.2% (104/114)	75.2% (152/202)	0.0005
Aortoiliac segment occlusion	% (n/N)	11.1% (35/316)	6.1% (7/114)	13.9% (28/202)	0.0401
Femoropopliteal segment occlusion	% (n/N)	73.1% (231/316)	78.9% (90/114)	69.8% (141/202)	0.0868
Femoropopliteal bypass occlusion	% (n/N)	22.8% (72/316)	17.5% (20/114)	25.7% (52/202)	0.1241
Femoro-femoral cross bypass occlusion	% (n/N)	0.6% (2/316)	0	1.0% (2/202)	0.5373
Leg of bifurcation stentgraft occlusion	% (n/N)	0.3% (1/316)	0	0.5% (1/202)	1.0000
Ileofemoral bypass occlusion	% (n/N)	0.3% (1/316)	0.9% (1/114)	0	0.3608
Deep femoral artery occlusion	% (n/N)	10.1% (32/316)	5.3% (6/114)	12.9% (26/202)	0.0332
In-stent occlusion	% (n/N)	23.4% (74/316)	21.9 % (24/114)	24.3 % (49/202)	0.6800
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	50.0% (57/114)	68.3% (138/202)	0.0017
Number of patent calf vessels before treatment	n Mean ± SD Median Range	$316 \\ 0.9 \pm 1.1 \\ 0.0 \\ 0.0, 4.0$	114 1.3 ± 1.2 1.0 0.0, 3.0	$\begin{array}{c} 202 \\ 0.7 \pm 1.0 \\ 0.0 \\ 0.0, 4.0 \end{array}$	<.0001
ABI before treatment	n Mean ± SD Median Range	309 0.1 ± 0.2 0.0 0.0, 0.6	108 0.2 ± 0.2 0.3 0.0, 0.6	201 0.1 ± 0.1 0.0 0.0, 0.6	<.0001

Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB.

Characteristics	Summary Statistics	All ALI Subjects	ALI IIA	ALI IIB	p-value
Age (years)	n	202	56	146	0.2113
rige (Jeurs)	Mean ± SD	72.6 ± 12.2	70.8 ± 12.9	73.2 ± 11.9	0.2113
	Median	73.0	73.0	74.0	
	Range	23.0, 96.0	23.0, 96.0	43.0, 96.0	
Male	% (n/N)	56.4% (114/202)	62.5% (35/56)	54.1% (79/146)	0.4079
Diabetes	% (n/N)	32.2% (65/202)	21.4% (12/56)	36.3% (53/146)	0.0452
Smoking history	% (n/N)	49.0% (99/202)	60.7% (34/56)	44.5% (65/146)	0.0425
Hyperlipidaemia	% (n/N)	37.6% (76/202)	50.0% (28/56)	32.9% (48/146)	0.0344
Hypertension	% (n/N)	75.2% (152/202)	71.4% (40/56)	76.7% (112/146)	0.4685
Cardiac disease	% (n/N)	46.0% (93/202)	41.1% (23/56)	47.9% (70/146)	0.4319
Arrhythmias	% (n/N)	30.7% (62/202)	28.6% (16/56)	31.5% (46/146)	0.7357
Cerebrovascular disease	% (n/N)	28.2% (57/202)	17.9% (10/56)	32.2% (47/146)	0.0543
Malignant disease	% (n/N)	6.9% (14/202)	5.4% (3/56)	7.5% (11/146)	0.7615
Renal insufficiency	% (n/N)	23.4% (74/316)	17.5% (20/114)	26.7% (54/202)	0.0726
Symptoms duration	n	202	56	146	0.0004
(days)	Mean ± SD	4.1±4.5	6.8±5.3	3.1±3.6	
	Median	2.0	6.5	2.0	
	Range	0.04, 14.0	0.08, 14.0	0.04, 14.0	
Claudication	% (n/N)	15.3% (31/202)	39.3% (22/56)	6.2% (9/146)	<.0001
	% (n/N)				
Rest pain	% (n/N)	83.7% (169/202)	62.5% (35/56)	91.8% (134/146)	<.0001
Tissue defect	% (n/N)	10.4% (21/202)	10.7% (6/56)	10.3% (15/146)	1.000
Target occlusion cause: Embolism	% (n/N)	24.8% (50/202)	14.3% (8/56)	28.8% (42/146)	0.0442
Target occlusion cause: Thrombosis	% (n/N)	75.2% (152/202)	85.7% (48/56)	71.2% (104/146)	0.0442

Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB

Characteristics	Summary Statistics	All Subjects	ALI IIA	ALI IIB	p-value
Target occlusion length (mm)	n Mean ± SD Median Range	202 244.6 ± 152.4 200.0 $20.0, 590.0$	56 215.5 ± 150.2 150.0 $20.0, 550.0$	146 255.7 ± 152.3 220.0 20.0, 590.0	0.0938
Aortoiliac segment occlusion	% (n/N)	13.9 % (28/202)	14.3 % (8/56)	13.7 % (20/146)	1.000
Femoropopliteal segment occlusion	% (n/N)	69.8% (141/202)	69.6% (39/56)	69.9% (102/146)	1.000
Femoropopliteal bypass	% (n/N)	25.7 % (52/202)	25.0 % (14/56)	26.0 % (38/146)	1.000
Leg of bifurcation stentgraft occlusion	% (n/N)	0.5% (1/202)	1.8% (1/56)	0.5% (1/202)	0.2772
Ileofemoral bypass occlusion	% (n/N)	25.7% (52/202)	25.0% (14/56)	26.0% (38/146)	1.000
Deep femoral artery occlusion	% (n/N)	12.9% (26/202)	5.4% (3/56)	15.8% (23/146)	0.0597
In-stent occlusion	% (n/N)	24.3% (49/202)	33.9% (19/56)	20.5% (30/146)	0.0657
Additional infrapopliteal occlusion	% (n/N)	68.3% (138/202)	57.1% (32/56)	72.6% (106/146)	0.0427
No. of patent calf vessles before treatment	n Mean ± std Median Range	$\begin{array}{c} 202 \\ 0.7 \pm 1.0 \\ 0.0 \\ 0.0, 4.0 \end{array}$	$56 \\ 1.4 \pm 1.1 \\ 1.0 \\ 0.0, 3.0$	$ \begin{array}{c} 146 \\ 0.4 \pm 0.9 \\ 0.0 \\ 0.0, 4.0 \end{array} $	<.0001
ABI before treatment	n Mean ± SD Median Range	$201 \\ 0.1 \pm 0.1 \\ 0.0 \\ 0.0, 0.6$	$55 \\ 0.2 \pm 0.2 \\ 0.2 \\ 0.0, 0.6$	$146 \\ 0.0 \pm 0.1 \\ 0.0 \\ 0.0, 0.4$	<.0001

Table 5. Demographics, concomitant disease, ischaemia classification and symptoms: thrombosis vs. embolism

Characteristics	Summary Statistics	All Subjects	Thrombosis	Embolism	p-value
Age (years)	n Mean ± SD Median Range	$31670.9 \pm 12.071.023.0, 96.0$	256 70.2 ± 11.3 70.0 43.0, 96.0	60 73.7 ± 14.2 76.0 23.0, 94.0	0.0054
Male	% (n/N)	58.2% (184/316)	63.7% (163/256)	35.0% (21/60)	<.0001
Female	% (n/N)	41.8% (132/316)	36.3% (93/256)	65.0% (39/60)	<.0001
Diabetes	% (n/N)	30.7% (97/316)	30.1% (77/256)	33.3% (20/60)	0.6425
Smoking history	% (n/N)	54.4% (172/316)	59.8% (153/256)	31.7% (19/60)	<.0001
Hyperlipidaemia	% (n/N)	38.9% (123/316)	39.5% (101/256)	36.7% (22/60)	0.7692
Hypertension	% (n/N)	74.7% (236/316)	74.6% (191/256)	75.0% (45/60)	1.0000
Cardiac disease	% (n/N)	42.1% (133/316)	37.5% (96/256)	61.7% (37/60)	0.0008
Arrhythmias	% (n/N)	25.6% (81/316)	19.5% (50/256)	51.7% (31/60)	<.0001
Cerebrovascular disease	% (n/N)	25.0% (79/316)	26.6% (68/256)	18.3% (11/60)	0.2458
Malignant disease	% (n/N)	7.3% (23/316)	7.8% (20/256)	5.0% (3/60)	0.5874
Renal insufficiency	% (n/N)	23.4% (74/316)	23.8% (61/256)	21.7% (13/60)	0.8657
Subacute ischaemia	% (n/N)	36.1% (114/316)	40.6% (104/256)	16.7% (10/60)	0.0005
Acute ischaemia	% (n/N)	63.9% (202/316)	59.4% (152/256)	83.3% (50/60)	0.0005
Acute ischaemia class IIA	% (n/N)	27.7% (56/202)	31.6% (48/152)	16.0% (8/50)	0.0442
Acute ischaemia class IIB	% (n/N)	72.3% (146/202)	68.4% (104/152)	84.0% (42/50)	0.0442
Claudication	% (n/N)	29.1% (92/316)	32.4% (83/256)	15.0% (9/60)	0.0071
Critical limb ischemia	% (n/N)	23.4% (74/316)	26.6% (68/256)	10.0% (6/60)	0.0062
Rest pain	% (n/N)	74.4% (235/316)	73.8% (189/256)	76.7% (46/60)	0.7436
Tissue defect	% (n/N)	14.9% (47/316)	17.2% (44/256)	5.0% (3/60)	0.0151

Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism

Characteristics	Summary Statistics	All Subjects	Thrombosis	Embolism	p-value
Target lesion length (mm)	n Mean ± SD Median Range	316 229.2 ± 148.1 200.0 $15.0, 650.0$	256 246.6 ± 150.4 220.0 15.0, 650.0	60 155.0 ± 111.7 125.0 $20.0, 480.0$	<.0001
Aortoiliac segment	% (n/N)	11.1% (35/316)	10.2% (26/256)	15.0% (9/60)	0.3588
Femoropopl segment	% (n/N)	73.1% (231/316)	68.0% (174/256)	95.0% (57/60)	<.0001
Femoropopl bypass	% (n/N)	22.8% (72/316)	27.7% (71/256)	1.7% (1/60)	<.0001
Femo-femoral cross bypass	% (n/N)	0.6% (2/316)	0.8% (2/256)		
Leg of bifurcation stentgraft	% (n/N)	0.3% (1/316)	0.4% (1/256)		
Ileofemoral bypass	% (n/N)	0.3% (1/316)	0.4% (1/256)		
Deep femoral artery	% (n/N)	10.1% (32/316)	7.0% (18/256)	23.3% (14/60)	0.0006
In-stent occlusion	% (n/N)	23.4% (74/316)	27.7% (71/256)	5.0% (3/60)	<.0001
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	59.0% (151/256)	73.3% (44/60)	0.0403
No. of patent calf vessles before treatment	n Mean ± SD Median Range	$316 \\ 0.9 \pm 1.1 \\ 0.0 \\ 0.0, 4.0$	$256 \\ 1.0 \pm 1.1 \\ 1.0 \\ 0.0, 3.0$	$60 \\ 0.4 \pm 0.9 \\ 0.0 \\ 0.0, 4.0$	<.0001
ABI before treatment	n Mean ± SD Median Range	309 0.1 ± 0.2 0.0 0.0, 0.6	$250 \\ 0.14 \pm 0.17 \\ 0.0 \\ 0.0, 0.6$	59 0.07 ± 0.14 0.0 0.0, 0.5	0.0016

Table 7. Age, concomitant disease, symptoms, ischaemia classification, occlusion length and location: female vs. male gender

Characteristics	Summary Statistics	All Subjects	Female	Male	p-value
Age (years)	n Mean ± SD Median	316 70.9 ± 12.0 71.0	132 75.1 ± 11.4 76.5	184 67.9 ± 11.5 67.5	<.0001
Diabetes	Range % (n/N)	23.0, 96.0	23.0, 96.0	31.0, 94.0 28.8% (53/184)	0.3903
Smoking history	% (n/N)	54.4% (172/316)	36.4% (48/132)	67.4% (124/184)	<.0001
Hyperlipidaemia	% (n/N)	38.9% (123/316)	41.7% (55/132)	37.0% (68/184)	0.4147
<u> </u>	% (n/N)	74.7% (236/316)	81.1% (107/132)	70.1% (129/184)	0.0355
Hypertension Cardiac disease	% (n/N)	42.1% (133/316)	42.4% (56/132)	41.8% (77/184)	1.0000
Arrhythmias	% (n/N)	, ,	1 1		0.0017
Cerebrovascular disease	% (n/N)	25.6% (81/316)	34.8% (46/132)	19.0% (35/184)	1.0000
	` ′	25.0% (79/316)	25.0% (33/132)	25.0% (46/184)	
Malignant disease	% (n/N)	7.3% (23/316)	6.8% (9/132)	7.6% (14/184)	0.8301
Renal insufficiency	% (n/N)	23.4% (74/316)	17.4% (23/132)	27.7% (51/184)	0.0429
Acute limb ischaemia category IIA	% (n/N)	27.7% (56/202)	23.9% (21/88)	30.7% (35/114)	0.3420
Acute limb ischaemia category IIB	% (n/N)	72.3% (146/202)	76.1% (67/88)	69.3% (79/114)	0.3420
Claudication	% (n/N)	29.1% (92/316)	23.5% (31/132)	33.2% (61/184)	0.0785
Critical limb ischaemia	% (n/N)	23.4% (74/316)	21.2% (28/132)	25.0% (46/184)	0.5011
Rest pain	% (n/N)	74.4% (235/316)	78.8% (104/132)	71.2% (131/184)	0.1509
Tissue defect	% (n/N)	14.9% (47/316)	9.8% (13/132)	18.5% (34/184)	0.0375
Target occlusion cause: Embolism	% (n/N)	19.0% (60/316)	29.5% (39/132)	11.4% (21/184)	<.0001
Target occlusion cause: Thrombosis	% (n/N)	81.0% (256/316)	70.5% (93/132)	88.6% (163/184)	<.0001
Target occlusion length (mm)	n Mean ± SD Median Range	316 229.2 ± 148.1 200.0 $15.0, 650.0$	132 221.0 ± 142.1 200.0 $20.0, 590.0$	$ \begin{array}{r} 184 \\ 235.1 \pm 152.5 \\ 200.0 \\ 15.0, 650.0 \end{array} $	0.5290
Aortoiliac segment	% (n/N)	11.1% (35/316)	14.4% (19/132)	8.7% (16/184)	0.1453
Femoropopliteal segment	% (n/N)	73.1% (231/316)	79.5% (105/132)	68.5% (126/184)	0.0296
Femoropopliteal bypass	% (n/N)	22.8% (72/316)	14.4% (19/132)	28.8% (53/184)	0.0027
Femo-femoral cross bypass	% (n/N)	0.6% (2/316)	0.8% (1/132)	0.5% (1/184)	1.0000
Leg of bifurcation stentgraft	% (n/N)	0.3% (1/316)		0.5% (1/184)	1.0000
Ileofemoral bypass	% (n/N)	0.3% (1/316)		0.5% (1/184)	1.0000
Deep femoral artery	% (n/N)	10.1% (32/316)	15.2% (20/132)	6.5% (12/184)	0.0142
In-stent occlusion	% (n/N)	23.4% (74/316)	24.2% (32/132)	22.8% (42/184)	0.7888
Additional infrapopliteal occlusion	% (n/N)	61.7% (195/316)	62.9% (83/132)	60.9% (112/184)	0.7266
Number of patent calf vessels	n Mean ± SD Median Range	$316 \\ 0.9 \pm 1.1 \\ 0.0 \\ 0.0, 3.0$	$132 \\ 0.9 \pm 1.1 \\ 0.0 \\ 0.0, 3.0$	$184 \\ 1.0 \pm 1.1 \\ 0.0 \\ 0.0, 3.0$	0.6844
ABI before treatment	n Mean ± SD Median Range	309 0.1 ± 0.2 0.0 0.0, 0.6	129 0.12 ± 0.16 0.0 0.0, 0.6	$\begin{array}{c} 180 \\ 0.14 \pm 0.17 \\ 0.0 \\ 0.0, 0.6 \end{array}$	0.2715